Prader-Willi Syndrome
SunTrust said it hasnt changed its benefit-risk profile for Zafgen Inc (NASDAQ: ZFGN)s beloranib, citing that thromboembolic risks linger on the obesity drug that showed statistically and clinically significant improvements in body weight and glycemic control in a mid-stage trial. Related Link:... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:
Zafgen Beloranib Edward Nash Soleno Therapeutics Inc Program In Prader Willi Syndromemonday Health Care Zafgen Inc
Source: benzinga.com